10 Res'd 2017 10 0 5 NOV 2994

PATENT COOPERATION TREAT

From the INTERNATIONAL SEARCHING AUTHORITY

То:		PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY		
see form PCT/ISA/2	20			
			(PCT Rule 43bis.1)	
		Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)		
Applicant's or agent's file reference see form PCT/ISA/220		FOR FURTHER ACTION See paragraph 2 below		
International application No. PCT/IB2004/000396	International filing date (05.02.2004	(day/month/year)	Priority date (day/month/year) 13.02.2003	
International Patent Classification (IP6 B65D81/32, B65D85/804	C) or both national classification	and IPC		
Applicant I.M.A. INDUSTRIA MACCHIN	E AUTOMATICHE S.P.A	•		

1.	This opinion co	This opinion contains indications relating to the following items:				
	☑ Box No. I	Box No. I Basis of the opinion				
☐ Box No. II Priority						
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial a						
☐ Box No. IV , Lack of unity of invention						
	Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	🖾 Box No. VI	Certain documents cited				
☐ Box No. VII Certain defects in the international application						
	☐ Box No. VIII	Certain observations on the international application				
2.	FURTHER ACTION					
	If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.					

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016

Authorized Officer

Bridault, A

Telephone No. +31 70 340-3224



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY



_	Вох	No	. I Basis of the opinion			
1.	With regard to the language , this opinion has been established on the basis of the international application in the language in which it was field, unless otherwise indicated under this item.					
		lan	s opinion has been established on the basis of a translation from the original language into the following guage , which is the language of a translation furnished for the purposes of international search der Rules 12.3 and 23.1(b)).			
2.	. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:					
	a. type of material:					
)	a sequence listing			
			table(s) related to the sequence listing			
	b. format of material:					
			in written format			
			in computer readable form			
	c. tiı	me (of filing/furnishing:			
			contained in the international application as filed.			
			filed together with the international application in computer readable form.			
]	furnished subsequently to this Authority for the purposes of search.			
3.		has	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.			
1	Additional comments:					



	Вох	No. II	Priority					
1.	\boxtimes	☐ The following document has not been furnished:						
		\boxtimes	copy of the earlier a	pplicatio	n whose prio	rity has been claimed (Rule 43bis.1 and 66.7(a)).		
			translation of the ea	rlier app	lication whos	e priority has been claimed (Rule 43bis.1 and 66.7(b)).		
		Consec neverth	quently it has not been establish	en possik ned on th	ole to conside le assumptio	er the validity of the priority claim. This opinion has n that the relevant date is the claimed priority date.		
2.	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.							
3.	Additional observations, if necessary:							
	Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
1.	Stat	ement						
	Nov	elty (N)		Yes: No:	Claims Claims	3, 4, 6, 8-13 1, 2, 5, 7		
	Inve	ntive st	ep (IS)	Yes: No:	Claims Claims	6, 10, 11 1-5, 7-9 12, 13		
	Indu	ıstrial ap	oplicability (IA)	Yes: No:	Claims Claims	1-13		
2.	Cita	tions an	nd explanations					
	see	separa	te sheet					
	<u> </u>							
	Box	No. VI	Certain documen	ts cited				

1. Certain published documents (Rules 43bis.1 and 70.10)

and / or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

Re Item V.

The following documents are referred to in this communication: 1

D1: CH 688 686 A D2: EP 0 007 876 A

2 **INDEPENDENT CLAIM 1**

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT.

Document D1 discloses (the references in parenthesis applying to this document) a capsule (1) used to prepare an infused beverage, comprising a first container (71) made of a substantially flexible material and containing a powered infusion substance (column 3, line 49), and a second container (7), attached to the first container, made of substantially rigid material and containing a powdered soluble substance (column 3, lines 34-35).

D1 discloses therefore, in one of its embodiments, a capsule according to claim 1.

- 3 DEPENDENT CLAIMS 2-5, 7-9, 12, 13
- Dependent claims 2, 5 and 7 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty (Article 33(2) PCT). The reasons therefor are the following:
 - claim 2: D1 mentions heat sealing (column 2, line 54);
 - claim 5: the capsule of D1 has a sheet of protective material (41); and
 - claim 7: the capsule of D1 can be made of plastics (column 2, lines 25-30).
- 3.2 Dependent claims 3, 4, 8, 9, 12 and 13 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step (Article 33(3) PCT). The reasons therefor are the following:

- claims 3 and 4: D1 mentions that the containers are joined by any suitable means (column 2, line 53). Gluing and ultrasound sealing are such well known means;
- claims 8 and 9: a sealed hole as in these claims is disclosed in D2; and
- claims 12 and 13: these substances are largely used and the capsule of D1 is obviously made for containing them.

4 DEPENDENT CLAIMS 6, 10, 11

The combination of the features of dependent claims 6, 10, 11 are neither known from, nor rendered obvious by, the available prior art. The reasons are that the available prior art does not suggest the combination of a pod with a rigid container for making a D1-type of capsule.